Martin Tolstrup
Aarhus University Hospital
118 Papers
650 Citations
Martin Tolstrup is an academic researcher from Aarhus University Hospital. The author has contributed to research in topics: Medicine & Immune system. The author has an hindex of 27, co-authored 82 publications.
Chat about Author
Papers
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A Rasmussen,Martin Tolstrup,Christel R. Brinkmann,Rikke Olesen,Christian Erikstrup,Ajantha Solomon,Anni Winckelmann,Sarah Palmer,Charles A. Dinarello,Maria J. Buzon,Maria J. Buzon,Mathias Lichterfeld,Mathias Lichterfeld,Sharon R Lewin,Sharon R Lewin,Lars Østergaard,Ole S. Søgaard +16 more
TL;DR: Panobinostat effectively disrupts HIV latency in vivo and is a promising candidate for future combination clinical trials aimed at HIV eradication, however, panobinostats did not reduce the number of latently infected cells and this approach may need to be combined with others to significantly affect the latent HIV reservoir.
603
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
Ole S. Søgaard,Mette E. Graversen,Steffen Leth,Rikke Olesen,Christel R. Brinkmann,Sara K. Nissen,Anne Sofie Høgh Kølbæk Kjær,Mariane H. Schleimann,Paul W. Denton,William J. Hey-Cunningham,Kersten K. Koelsch,Giuseppe Pantaleo,Kim Krogsgaard,Maja A. Sommerfelt,Rémi Fromentin,Nicolas Chomont,Thomas A Rasmussen,Lars Østergaard,Martin Tolstrup +18 more
TL;DR: A proof-of-concept phase Ib/IIa trial where 6 aviremic HIV-1 infected adults received intravenous 5 mg/m2 romidepsin (Celgene) once weekly for 3 weeks while maintaining ART demonstrates that significant reversal of HIV- 1 latency in vivo is possible without blunting T cell-mediated immune responses.
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
Thomas A Rasmussen,Ole S. Søgaard,Christel R. Brinkmann,Fiona Wightman,Sharon R Lewin,Jesper Melchjorsen,Charles A. Dinarello,Lars Østergaard,Martin Tolstrup +8 more
TL;DR: Panobinostat was significantly more potent than all other HDAC inhibitors and induced virus production even in the very low concentration range 8–31 nM and is now being advanced into clinical testing against latent HIV infection.
Reversal of Latency as Part of a Cure for HIV-1
TL;DR: Here, the use of pharmacological agents to reverse HIV-1 latency will be explored as a therapeutic strategy towards a cure, while clinical trials of latency-reversing agents LRAs) have demonstrated their ability to increase production of latent HIV- 1, but such interventions have not had an effect on the size of the latent virus reservoir.
93
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
Jesper Damsgaard Gunst,Marie H. Pahus,Miriam Rosás-Umbert,I-Na Lu,Thomas Benfield,Henrik Nielsen,A. Johansen,Rajesh Mohey,Lars Østergaard,Vibeke Klastrup,Maryam Khan,Mariane H. Schleimann,Rikke Olesen,Henrik Støvring,Paul W. Denton,Natalie N. Kinloch,Dennis C Copertino,Adam R. Ward,Winiffer D. Conce Alberto,S. D. Nielsen,Maria C. Puertas,Victor Ramos,Jacqueline D. Reeves,Christos J. Petropoulos,Javier Martinez-Picado,Zabrina L. Brumme,R. Brad Jones,Julie Fox,Martin Tolstrup,Michel C. Nussenzweig,Marina Caskey,Sarah Fidler,Ole S. Søgaard +32 more
TL;DR: In this paper , the authors investigated whether early intervention in newly diagnosed people with HIV-1 with a monoclonal anti-HIV-1 antibody with a CD4-binding site, 3BNC117, followed by a histone deacetylase inhibitor, romidepsin, shortly after ART initiation altered the course of HIV infection.